


FORM PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
P28506Application No.
10/550,013INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Use several sheets if necessary)

Applicant
Rudolf FAHRIG et al.Filing Date
September 23, 2005Group
Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
M.C.H.		6 5 8 9 9 4 1	07/08/03	FAHRIG et al.	—	—	
M.C.H.	2004	0 1 2 7 4 5 4	07/01/04	FAHRIG et al.	—	—	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
M.C.H.		0 8 0 6 9 5 6	08/28/02	E.P.O	—	—	
	01	/ 0 7 0 8 8	02/01/01	W.I.P.O	—	—	
	96	/ 2 3 5 0 6	08/08/96	W.I.P.O	—	—	
M.C.H.	02	/ 0 6 7 9 5 1	09/06/02	W.I.P.O	—	—	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

M.C.H.	1	E. de Clercq, "Potential of Bromovinyldeoxyuridine in Anticancer Chemotherapy," Anticancer Research, vol. 6, no. 4, July 1986, pp. 549-556.
	2	R. Fahrig et al., "Prevention of adriamycin-induced mdr1 gene amplification and expression in mouse leukemia cells by simultaneous treatment with the anti-recombinogen bromovinyldeoxyuridine," Anti-Cancer Drug Design (2000),15(5), pp. 307-312 (incorrectly dated 2001 in the International Search Report).
	3	M. Iigo et al., "Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on Life-Span and 5-Fluorouracil metabolism in Mice with Hepatic Metastases," Euro. J. Cancer, vol. 26, no. 10, 1990, pp. 1089-1092.
	4	B. Degreve et al., "Selection of HSV-1 TK Gene-Transfected murine Mammary Carcinoma Cells Resistant to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and ganciclovir (GCV)" Gene Therapy (2000), 7(18), pp. 1543-52.
	5	J. Balzarini, "Increased Sensitivity of Thymine Kinase Deficient (TK-) Tumor Cell Lines to the Cell Growth Inhibitory Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and Related Compounds," Anticancer Research, vol. 6, no. 5, 1986, pp. 1077-1084.
	6	S. Pancheva, "Methotrexate Potentiates Anti-Herpes Simplex Virus Type 1 Activity of E-5-(2-bromovinyl)-2'-deoxyuridine," Acta virologica, vol. 39, no. 2, 1995, pp. 117-119.
	7	J. Kerr et al., "Apoptosis: A Basic Biological Phenomenon with Wide-Ranging Implications in Tissue Kinetics," Br. J. Cancer, (1972) 26, pp. 239-257.
	8	R. Fahrig et al., "Induction or suppression of SV40 amplification by genotoxic carcinogens, non-genotoxic carcinogens, or tumor promoters," Mutation Research 356 (1996) 217-224.
	9	R. Fahrig, "Anti-recombinogenic and convertible co-mutagenic effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and other 5-substituted nucleoside analogs in <i>S. cerevisiae</i> MP1," Mutation Research 372 (1996) 133-39.
M.C.H.	10	Hodnick et al., "Measurement of Dicumarol-Sensitive NADPH:(Menadione-Cytochrome c) Oxidoreductase Activity Results in an Artifactual Assay of DT-Diaphorase in Cell Sonicates," Anal. Biochem. 252(1), 1997, 165-168.

EXAMINER

DATE CONSIDERED

6/23/07

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.